The global antiepileptic drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2022-2029).
Antiepileptic drugs are medications that are developed for the idiopathic and asymptomatic treatment of seizures and epilepsy. In addition to epilepsy and seizures, antiepileptic drugs can also be taken for the treatment of neuropathic pain.
The global antiepileptic drugs market growth is driven by the expanding base of the geriatric population, dietary habits are some of the significant factors that are triggering the growth of the global antiepileptic drugs market.
A large number of pipeline drugs is driving the growth of the market
The market is driven by advancements in drugs modification. Over the past several periods, the number of available antiepileptic drugs has more than doubled, many of the presently available antiepileptic drugs have basic pharmacokinetics and more small effects on liver metabolism that converts into a lower rate of side effects.
A large number of pipeline drugs is driving the growth of the market. The expected launch of drugs currently in the pipeline, such as Ganaxolone by Marinus Pharmaceuticals, Inc., Perampanel by Eisai Co., Ltd., USL261 by Upsher Smith Laboratories, Inc., and YKP3089 by SK Life Sciences, Inc. is a high impact rendering driver of the epilepsy drugs market.
VX765 by Vertex Pharmaceuticals, Inc. and YKP3089 by SK Life Sciences, Inc. are some of the Phase IIb drugs. Phase III clinical trials include NRL-1 intranasal Diazepam, Carbamazepine IV, Diazepam Auto-injector (Vanquix), and Topiramate Extended-Release (USL-255).
Rising awareness levels about epilepsy coupled with strategic alliances are anticipated to stimulate market growth.
The increasing number of people being affected by different types of cancer is another factor driving the growth of the antiepileptic drug market. Chemotherapy is one of the standard treatments used to deal with cancer and is also accompanied by side effects of nausea and vomiting. Chemotherapy accounts for the largest share of all the applications of the global antiepileptic drugs market. These factors are driving the growth of the market in the forecast period.
Rising generic competition is likely to hinder the market growth
However, the market is threatened by generic competition, which has risen dramatically in the face of patent expirations among various major branded antiepileptic drugs. This factor will hamper the market growth in the forecast period.
COVID-19 Impact Analysis
There is no evidence that people with epilepsy alone have a weakened immune system. They should not be considered “immunocompromised” and would not have an “immune deficiency” from having seizures. People with different types of epilepsy, certain causes of epilepsy or other health conditions may have factors affecting their immune system. However, patients with tumour-related, drug-resistant epilepsy, insomnia, and economic difficulties are at a higher risk of increased seizure frequency. Some people with epilepsy regardless of seizure control have other health conditions that put them at higher risk from COVID-19.
Second generation anti-epileptics segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The second-generation anti-epileptics drugs are expected to hold the largest market share owing to several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.
Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018, one of the market players UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.
In September 2019, GW Pharmaceuticals, plc, a biopharmaceutical company headquartered in the U.K., unveiled that it received approval from the European Commission (EC) for EPIDYOLEX, an innovative drug that will be used for Dravet syndrome or Lennox‑Gastaut syndrome (LGS), as adjunctive therapy of seizures. It is meant for patients who are 2 years of age and older. It will be launched across Europe. These factors are driving the growth of the market in the forecast period.
The hospital pharmacy is expected to dominate the antiepileptic drugs market during the forecast period
The hospital pharmacies held the largest share in the antiepileptic drugs market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global antiepileptic drugs market
North America region is dominating the global antiepileptic drugs market accounted for the largest market share, owing to well-established health care infrastructure, technological advancements, and favourable government support in the region. The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer’s disease. About one per cent of Americans have some form of epilepsy, and nearly four per cent (1 in 26) will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson’s disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the antiepileptic drugs market.
The antiepileptic drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GW Pharmaceuticals, plc, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiepileptic drugs market globally.
Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Others. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.
Product Portfolio: The Company’s portfolio is comprised of drugs, generic medicines, food supplements, cosmetics, and medical devices such as cancer, cardiology, gynaecology, and diabetes.
Get your free sample proposal with a single click!